Northern Trust Corp Eloxx Pharmaceuticals, Inc. Transaction History

Northern Trust Corp

  • $586 Billion
  • Q2 2024

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

May 13, 2022
SELL
$0.4 - $0.72 $280 - $504
-700 Reduced 0.56%
123,669 $69,000
Q3 2021

Nov 15, 2021
SELL
$1.22 - $2.0 $15,253 - $25,006
-12,503 Reduced 9.13%
124,369 $202,000
Q2 2021

Aug 13, 2021
SELL
$1.35 - $3.36 $209,715 - $521,959
-155,345 Reduced 53.16%
136,872 $273,000
Q1 2021

May 12, 2021
SELL
$3.02 - $4.54 $90,243 - $135,664
-29,882 Reduced 9.28%
292,217 $970,000
Q4 2020

Feb 11, 2021
SELL
$2.42 - $4.48 $6,674 - $12,355
-2,758 Reduced 0.85%
322,099 $1.28 Million
Q3 2020

Nov 16, 2020
SELL
$2.53 - $3.4 $42,005 - $56,450
-16,603 Reduced 4.86%
324,857 $854,000
Q2 2020

Aug 14, 2020
BUY
$1.56 - $3.65 $39,867 - $93,279
25,556 Added 8.09%
341,460 $1.03 Million
Q1 2020

May 14, 2020
BUY
$1.96 - $7.96 $53,259 - $216,297
27,173 Added 9.41%
315,904 $619,000
Q4 2019

Feb 14, 2020
SELL
$3.19 - $7.56 $10,208 - $24,192
-3,200 Reduced 1.1%
288,731 $2.13 Million
Q3 2019

Nov 13, 2019
SELL
$4.37 - $9.91 $36,122 - $81,916
-8,266 Reduced 2.75%
291,931 $1.32 Million
Q2 2019

Aug 13, 2019
BUY
$8.77 - $12.49 $115,027 - $163,818
13,116 Added 4.57%
300,197 $2.99 Million
Q1 2019

May 13, 2019
BUY
$10.45 - $13.94 $57,966 - $77,325
5,547 Added 1.97%
287,081 $3.35 Million
Q4 2018

Feb 12, 2019
SELL
$10.43 - $17.39 $4,662 - $7,773
-447 Reduced 0.16%
281,534 $3.38 Million
Q3 2018

Nov 14, 2018
BUY
$11.95 - $19.63 $2.46 Million - $4.04 Million
205,893 Added 270.6%
281,981 $4.81 Million
Q2 2018

Sep 18, 2018
BUY
$8.75 - $23.27 $112,901 - $300,252
12,903 Added 20.42%
76,088 $1.3 Million
Q2 2018

Aug 14, 2018
BUY
$8.75 - $23.27 $552,868 - $1.47 Million
63,185 New
63,185 $1.08 Million

About Eloxx Pharmaceuticals, Inc.

ELOX Quotes by TradingView
  • Ticker ELOX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 86,656,200
  • Description
  • Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing ribosome modulation for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial for the treatment of cystic fibrosis and nephropathic cystinosis p...
More about ELOX
Track This Portfolio

Track Northern Trust Corp Portfolio

Follow Northern Trust Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email